Identification and validation of a blood- based diagnostic lipidomic signature of pediatric inflammatory bowel disease - UTU Research Portal

A1 Refereed original research article in a scientific journal

Identification and validation of a blood- based diagnostic lipidomic signature of pediatric inflammatory bowel disease

Authors: Salihovic, Samira; Nyström, Niklas; Mathisen, Charlotte Bache-Wiig; Kruse, Robert; Olbjørn, Christine; Andersen, Svend; Noble, Alexandra J.; Dorn-Rasmussen, Maria; Bazov, Igor; Perminow, Gøri; Opheim, Randi; Detlie, Trond Espen; Huppertz-Hauss, Gert; Hedin, Charlotte R. H.; Carlson, Marie; Öhman, Lena; Magnusson, Maria K.; Keita, Åsa V.; Söderholm, Johan D.; D’Amato, Mauro; Orešič, Matej; Wewer, Vibeke; Satsangi, Jack; Lindqvist, Carl Mårten; Burisch, Johan; Uhlig, Holm H.; Repsilber, Dirk; Hyötyläinen, Tuulia; Høivik, Marte Lie; Halfvarson, Jonas

Publisher: Springer Nature

Publication year: 2024

Journal: Nature Communications

Journal name in source: Nature communications

Journal acronym: Nat Commun

Article number: 4567

Volume: 15

Issue: 1

eISSN: 2041-1723

DOI: https://doi.org/10.1038/s41467-024-48763-7

Self-archived copy’s web address: https://research.utu.fi/converis/portal/detail/Publication/454780843

Abstract

Improved biomarkers are needed for pediatric inflammatory bowel disease. Here we identify a diagnostic lipidomic signature for pediatric inflammatory bowel disease by analyzing blood samples from a discovery cohort of incident treatment-naïve pediatric patients and validating findings in an independent inception cohort. The lipidomic signature comprising of only lactosyl ceramide (d18:1/16:0) and phosphatidylcholine (18:0p/22:6) improves the diagnostic prediction compared with high-sensitivity C-reactive protein. Adding high-sensitivity C-reactive protein to the signature does not improve its performance. In patients providing a stool sample, the diagnostic performance of the lipidomic signature and fecal calprotectin, a marker of gastrointestinal inflammation, does not substantially differ. Upon investigation in a third pediatric cohort, the findings of increased lactosyl ceramide (d18:1/16:0) and decreased phosphatidylcholine (18:0p/22:6) absolute concentrations are confirmed. Translation of the lipidomic signature into a scalable diagnostic blood test for pediatric inflammatory bowel disease has the potential to support clinical decision making.

Downloadable publication

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.

s41467-024-48763-7.pdf

Funding information in the publication:
Open access funding provided by Örebro University.